EARNINGS PER SHARE

9 Months Ended

Dec. 28, 2024

7. EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.


	Three Months Ended				Nine Months Ended
(In thousands, except per share amounts)	December 28, 2024		December 30, 2023		December 28, 2024		December 30, 2023
Basic EPS
Net income	$	37,494	$	31,241	$	109,698	$	97,191
Weighted average shares	50,286		50,768		50,709		50,679
Basic income per share	$	0.75	$	0.62	$	2.16	$	1.92
Diluted EPS
Net income	$	37,494	$	31,241	$	109,698	$	97,191
Basic weighted average shares	50,286		50,768		50,709		50,679
Net effect of common stock equivalents	353		677		439		715
Diluted weighted average shares	50,639		51,445		51,148		51,394
Diluted income per share	$	0.74	$	0.61	$	2.14	$	1.89

Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the applicable initial conversion prices, and consequently no shares have been included in diluted earnings per share for the conversion values of both convertible senior notes. For the three and nine months ended December 28, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of $0.8 million anti-dilutive shares for both periods. For the three and nine months ended December 30, 2023, weighted average shares outstanding, assuming dilution, excludes the impact of $0.6 million anti-dilutive shares for both periods.

Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36. As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.